Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

Completed · Phase 2

Conditions studied: Chronic Myelogenous Leukemia

In brief

The purpose of this study is to evaluate the anti-cancer activity and safety of Bay 43-006, in patients who have Chronic Myelogenous Leukemia that resisted to Gleevec treatment, one of the standard medication administered for these patients.

Key facts

Study ID

NCT00661180

Run by

Bayer

People needed

10

Starts

2004-01-01

Expected to finish

2005-02-01

Last updated by the study team

2014-12-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Portland, Oregon, United States
• Study site — Lyon, France
• Study site — Paris, France
• Study site — Poitiers, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.